Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Tunlametinib Capsules Versus Combination Chemotherapy of Investigator's Choice in Advanced NRAS-mutant Melanoma Patients Who Had Previously Received Immunotherapy

Next Previous
Trial Profile

Efficacy and Safety of Tunlametinib Capsules Versus Combination Chemotherapy of Investigator's Choice in Advanced NRAS-mutant Melanoma Patients Who Had Previously Received Immunotherapy

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tunlametinib (Primary) ; Carboplatin; Cisplatin; Dacarbazine; Paclitaxel; Temozolomide
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Kechow Pharma

Most Recent Events

  • 04 Jun 2024 According to trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology, this study is currently open for enrollment.
  • 04 Jun 2024 Status changed to recruiting, according to trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top